Primary cutaneous anaplastic large‐cell lymphoma with marked spontaneous regression of organ manifestation after SARS‐CoV‐2 vaccination
Thilo Gambichler, Stefanie Boms, S. Hessam, Iris Tischoff, Andrea Tannapfel, T. Lüttringhaus, Jayson Beckman, René Stranzenbach
Abstract
psychodermatology multidisciplinary team due to stable disease in our patient cohort.However, they may have a role in the treatment of some of our patients in the future should their condition become refractory to current therapy.The remission rate of NP was low.Out of the 40 patients, only 16 (40%) had improved at the time the data were collected and had been discharged.Of those, 14 were on a range of combination therapies and the remaining two were on monotherapy.Limitations of our study include lack of adjustment for confounding and inability to form conclusive inferences on treatment outcomes due to the study design and small patient cohort, although a cohort of 40 patients is relatively large in NP research.In conclusion, we acknowledge that the IFSI guidelines are a step forward towards a standardized treatment for NP; however, we are yet to see the most effective combination of treatments trialled in large-scale studies.We do believe that NP management is complex and requires a multidisciplinary approach within a specialist psychodermatology clinic.There remains hope with preliminary data available on monoclonal antibodies and Janus kinase inhibitors in NP. 5 However, at present based on our findings, patients with NP who showed improvements were on a combination of treatments that manage the skin and the mind concurrently, which is the main point we hope this study emphasizes.